FDA issues final guidance on OTC drug labelling - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA issues final guidance on OTC drug labelling



The FDA has issued the final draft of its Guidance for Industry titled “Labeling of Nonprescription Human Drug Products Marketed Without an Approved Application as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act: Questions and Answers.” The guidance is intended to help manufacturers, packers and distributors of such drug products comply with the new section 502(x) of the Federal Food, Drug, and Cosmetic Act.

Section 502(x) states that the label of an over-the-counter (OTC) drug marketed in the US without an approved application must include “a domestic address or domestic phone number through which the responsible person … may receive a report of a serious adverse event.” The guidance document clarifies the meaning of “domestic address” as the complete mailing address, so as not to be confused with the term “place of business” address often used by Congress.

The guidance describes the FDA’s recommendation for the use of an introductory statement before the domestic address or phone number that is required to appear on the product label. Several examples of such a statement are listed in the document. According to the guidance, the product label can include an e-mail address or website to which reports can be made, “provided that such email address or web site is in addition to the domestic phone number or domestic address ….”

Section 502(x) of the Act became effective on 22 December 2007, so the labeling requirements are already in effect. The FDA intends to “exercise enforcement discretion for the new labeling requirements until 30 September 2010,” with enforcement beginning immediately after this date.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here